Shanghai Junshi Biosciences Co., Ltd. (1877.HK)
HKD 16.26
(-0.49%)
HKD 16.26
(-0.49%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -2.45 Billion CNY | 7.32% |
| 2022 | -2.67 Billion CNY | -289.83% |
| 2021 | -685.33 Million CNY | 59.18% |
| 2020 | -1.67 Billion CNY | -119.65% |
| 2019 | -764.44 Million CNY | -12.5% |
| 2018 | -679.48 Million CNY | -129.84% |
| 2017 | -295.63 Million CNY | -103.55% |
| 2016 | -145.24 Million CNY | -79.11% |
| 2015 | -81.09 Million CNY | -91.77% |
| 2014 | -42.28 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -322.38 Million CNY | -30.74% |
| 2024 Q1 | -292.83 Million CNY | 69.67% |
| 2023 FY | -2.47 Billion CNY | 7.32% |
| 2023 Q1 | -633.21 Million CNY | 30.34% |
| 2023 Q3 | -291.31 Million CNY | 44.39% |
| 2023 Q4 | -965.64 Million CNY | -231.48% |
| 2023 Q2 | -523.84 Million CNY | 17.27% |
| 2022 Q3 | -781.23 Million CNY | -20.47% |
| 2022 Q1 | -383.14 Million CNY | -24.95% |
| 2022 FY | -2.67 Billion CNY | -289.83% |
| 2022 Q4 | -909.03 Million CNY | -16.36% |
| 2022 Q2 | -648.5 Million CNY | -69.26% |
| 2021 Q3 | -383.56 Million CNY | 18.22% |
| 2021 Q4 | -306.64 Million CNY | 20.05% |
| 2021 Q1 | 473.14 Million CNY | 178.61% |
| 2021 Q2 | -468.99 Million CNY | -199.12% |
| 2021 FY | -685.33 Million CNY | 59.18% |
| 2020 Q2 | -382.75 Million CNY | -78.68% |
| 2020 FY | -1.67 Billion CNY | -119.65% |
| 2020 Q4 | -601.91 Million CNY | -21.32% |
| 2020 Q3 | -496.15 Million CNY | -29.63% |
| 2020 Q1 | -214.21 Million CNY | 31.13% |
| 2019 Q1 | -207.29 Million CNY | 20.8% |
| 2019 Q4 | -311.04 Million CNY | -63.01% |
| 2019 Q3 | -190.8 Million CNY | -94.8% |
| 2019 Q2 | -97.95 Million CNY | 52.75% |
| 2019 FY | -764.44 Million CNY | -12.5% |
| 2018 Q1 | -91.36 Million CNY | 29.84% |
| 2018 Q3 | -159.31 Million CNY | 9.98% |
| 2018 FY | -679.48 Million CNY | -129.84% |
| 2018 Q2 | -176.97 Million CNY | -93.7% |
| 2018 Q4 | -261.73 Million CNY | -64.29% |
| 2017 FY | -295.63 Million CNY | -103.55% |
| 2017 Q3 | -71.74 Million CNY | 2.28% |
| 2017 Q4 | -130.21 Million CNY | -81.5% |
| 2017 Q2 | -73.42 Million CNY | -0.4% |
| 2017 Q1 | -73.12 Million CNY | -33.07% |
| 2016 FY | -145.24 Million CNY | -79.11% |
| 2016 Q1 | -25.5 Million CNY | 10.09% |
| 2016 Q4 | -54.95 Million CNY | 1.91% |
| 2016 Q3 | -56.02 Million CNY | -119.69% |
| 2016 Q2 | -25.5 Million CNY | 0.0% |
| 2015 Q4 | -28.36 Million CNY | 0.0% |
| 2015 Q2 | -12.17 Million CNY | 0.0% |
| 2015 Q1 | -12.17 Million CNY | 16.67% |
| 2015 FY | -81.09 Million CNY | -91.77% |
| 2015 Q3 | -28.36 Million CNY | -132.91% |
| 2014 Q3 | -14.61 Million CNY | -123.93% |
| 2014 FY | -42.28 Million CNY | 0.0% |
| 2014 Q2 | -6.52 Million CNY | 0.0% |
| 2014 Q1 | -6.52 Million CNY | 0.0% |
| 2014 Q4 | -14.61 Million CNY | 0.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Uni-Bio Science Group Limited | 67.76 Million HKD | 3726.258% |
| CK Life Sciences Int'l., (Holdings) Inc. | 897.95 Million HKD | 373.672% |